Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1188–1195. doi: 10.1016/j.ijrobp.2013.12.043

Figure 6. Mice cured of CT26-GUCY2C tumors by sequential RT-IT exhibit GUCY2C-dependent long-term antitumor protection.

Figure 6

(A) Mice were challenged with CT26-GUCY2C cells and cured with 8 Gy followed by therapeutic Ad5-GUCY2C vaccination. Fifty days following initial tumor challenge, cured and naïve mice were challenged with 4T1-WT in the left flank and 4T1-GUCY2C in the right flank and tumor volumes were measured longitudinally. (B) 4T1-WT and 4T1-GUCY2C tumor growth was equivalent in naïve mice. (C) In contrast, 4T1-GUCY2C tumor growth was inhibited, compared to 4T1-WT tumors, in mice previously cured of CT26-GUCY2C tumors.